Chin K. Rhee
Distinguished in Simple Pulmonary Eosinophilia

Chin K. Rhee

St. Vincent's Hospital, 
Suwon, KR 
Distinguished in Simple Pulmonary Eosinophilia
St. Vincent's Hospital, 
Suwon, KR 
OverviewLocationsClinical Research

Overview

Chin Rhee practices in Suwon, Republic of Korea. Mr. Rhee is rated as a Distinguished expert by MediFind in the treatment of Simple Pulmonary Eosinophilia. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchitis, Bone Marrow Transplant, and Lung Transplant.

His clinical research consists of co-authoring 373 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Simple Pulmonary Eosinophilia.

Gender
Male

Locations

St. Vincent's Hospital, Suwon, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: August 15, 2025
Intervention Type: Drug, Biological
Study Drug: Mepolizumab
Study Phase: Phase 3
Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations
Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations
Enrollment Status: Completed
Publish Date: April 10, 2024
Intervention Type: Other
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
View 2 Less Clinical Trials

373 Total Publications

Reply to Liu et al., Zhou et al., and Dong et al.
Reply to Liu et al., Zhou et al., and Dong et al.
Journal: American journal of respiratory and critical care medicine
Published: September 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rhee's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 34 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile